Rabies - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H2 2016, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 6, 3, 10, 4 and 1 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Rabies.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Rabies Overview 9
Therapeutics Development 10
Pipeline Products for Rabies - Overview 10
Pipeline Products for Rabies - Comparative Analysis 11
Rabies - Therapeutics under Development by Companies 12
Rabies - Therapeutics under Investigation by Universities/Institutes 14
Rabies - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Rabies - Products under Development by Companies 19
Rabies - Products under Investigation by Universities/Institutes 20
Rabies - Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
BioClonetics Immunotherapeutics, Inc. 22
Celltrion, Inc. 23
Curevac AG 24
Humabs BioMed SA 25
Indian Immunologicals Limited 26
Kaketsuken K.K. 27
Kamada Ltd. 28
Molecular Targeting Technologies, Inc. 29
NanoViricides, Inc. 30
Novavax, Inc. 31
PaxVax, Inc. 32
Prosetta Biosciences, Inc. 33
Sanofi Pasteur SA 34
Serum Institute of India Limited 35
Sinovac Biotech Ltd. 36
Synermore Biologics Co Ltd 37
Trellis Bioscience, Inc. 38
VBI Vaccines Inc 39
Zydus Cadila Healthcare Limited 40
Rabies - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(Ebola [Zaire] + rabies) (bivalent) vaccine - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CTP-19 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CV-8102 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IMT-504 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
KD-357 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
MAb-3 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Monoclonal Antibodies for Rabies - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Monoclonal Antibodies for Rabies - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Monoclonal Antibody for Rabies - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
nadorameran - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PAV-866 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
RabiCide-I - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
rabies [strain Wistar PM/WI 38-1503-3M] vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
rabies immune globulin (human) - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
rabies vaccine - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
rabies vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
rabies vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
rabies vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
rabies vaccine - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
rabies vaccine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
rabies vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
rabies vaccine - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
rabies vaccine 1 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Rabimabs - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
RVC-20 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
RVC-58 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
SII RMab - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
SO-57 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
SOJB - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
SYN-023 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Rabies - Dormant Projects 83
Rabies - Product Development Milestones 84
Featured News & Press Releases 84
Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment 84
Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 84
Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment 86
Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies 87
Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies 88
Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability 88
Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel 89
Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America 89
May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product 90
Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for Rabies, H2 2016 10
Number of Products under Development for Rabies - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Rabies - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 21
Rabies - Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 22
Rabies - Pipeline by Celltrion, Inc., H2 2016 23
Rabies - Pipeline by Curevac AG, H2 2016 24
Rabies - Pipeline by Humabs BioMed SA, H2 2016 25
Rabies - Pipeline by Indian Immunologicals Limited, H2 2016 26
Rabies - Pipeline by Kaketsuken K.K., H2 2016 27
Rabies - Pipeline by Kamada Ltd., H2 2016 28
Rabies - Pipeline by Molecular Targeting Technologies, Inc., H2 2016 29
Rabies - Pipeline by NanoViricides, Inc., H2 2016 30
Rabies - Pipeline by Novavax, Inc., H2 2016 31
Rabies - Pipeline by PaxVax, Inc., H2 2016 32
Rabies - Pipeline by Prosetta Biosciences, Inc., H2 2016 33
Rabies - Pipeline by Sanofi Pasteur SA, H2 2016 34
Rabies - Pipeline by Serum Institute of India Limited, H2 2016 35
Rabies - Pipeline by Sinovac Biotech Ltd., H2 2016 36
Rabies - Pipeline by Synermore Biologics Co Ltd, H2 2016 37
Rabies - Pipeline by Trellis Bioscience, Inc., H2 2016 38
Rabies - Pipeline by VBI Vaccines Inc, H2 2016 39
Rabies - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Assessment by Combination Products, H2 2016 42
Number of Products by Stage and Target, H2 2016 44
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Rabies - Dormant Projects, H2 2016 83